The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia, Critical and Emergency Care Group
  4. Cochrane Back and Neck Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Common Mental Disorders Group
  10. Cochrane Consumers and Communication Group
  11. Cochrane Cystic Fibrosis and Genetic Disorders Group
  12. Cochrane Dementia and Cognitive Improvement Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Effective Practice and Organisation of Care Group
  16. Cochrane ENT Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
  21. Cochrane Gynaecology and Fertility Group
  22. Cochrane Haematological Malignancies Group
  23. Cochrane Heart Group
  24. Cochrane Hepato-Biliary Group
  25. Cochrane HIV/AIDS Group
  26. Cochrane Hypertension Group
  27. Cochrane IBD Group
  28. Cochrane Incontinence Group
  29. Cochrane Infectious Diseases Group
  30. Cochrane Injuries Group
  31. Cochrane Kidney and Transplant Group
  32. Cochrane Lung Cancer Group
  33. Cochrane Metabolic and Endocrine Disorders Group
  34. Cochrane Methodology Review Group
  35. Cochrane Movement Disorders Group
  36. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group
  37. Cochrane Musculoskeletal Group
  38. Cochrane Neonatal Group
  39. Cochrane Neuromuscular Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Pregnancy and Childbirth Group
  43. Cochrane Public Health Group
  44. Cochrane Schizophrenia Group
    1. About this group
    2. Reviews
      1. Acetylcholinesterase inhibitors for schizophreniaReview
      2. Acupuncture for schizophreniaReview
      3. Advance treatment directives for people with severe mental illnessReview
      4. Amisulpride for schizophreniaReview
      5. Amisulpride versus other atypical antipsychotics for schizophreniaReview
      6. Amphetamines for schizophreniaReview
      7. Anticholinergic medication for neuroleptic-induced tardive dyskinesiaReview
      8. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophreniaReview
      9. Anticholinergics for neuroleptic-induced acute akathisiaReview
      10. Antidepressants for people with both schizophrenia and depressionReview
      11. Antidepressants for the negative symptoms of schizophreniaReview
      12. Antiglucocorticoid and related treatments for psychosisReview
      13. Antioxidant treatments for schizophreniaReview
      14. Antipsychotic drug treatment for elderly people with late-onset schizophreniaReview
      15. Antipsychotic drugs for non-affective psychosis during pregnancy and postpartumReview
      16. Antipsychotic medication for childhood-onset schizophreniaReview
      17. Antipsychotic medication for early episode schizophreniaReview
      18. Antipsychotic medication for elderly people with schizophreniaReview
      19. Antipsychotic medication versus placebo for people with both schizophrenia and learning disabilityReview
      20. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsReview
      21. Aripiprazole for schizophreniaReview
      22. Aripiprazole versus other atypical antipsychotics for schizophreniaReview
      23. Aripiprazole versus placebo for schizophreniaReview
      24. Aripiprazole versus typical antipsychotic drugs for schizophreniaReview
      25. Art therapy for schizophrenia or schizophrenia-like illnessesReview
      26. 'As required' medication regimens for seriously mentally ill people in hospitalReview
      27. Asenapine versus placebo for schizophreniaReview
      28. Assertive community treatment for people with severe mental disordersReviewWithdrawn
      29. Atypical antipsychotics for people with both schizophrenia and depressionReview
      30. Atypical antipsychotics for psychosis in adolescentsReview
      31. Ayurvedic medicine for schizophreniaReview
      32. Benperidol for schizophreniaReview
      33. Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnessesReview
      34. Benzodiazepines for neuroleptic-induced acute akathisiaReview
      35. Benzodiazepines for neuroleptic-induced tardive dyskinesiaReview
      36. Benzodiazepines for psychosis-induced aggression or agitationReview
      37. Benzodiazepines for schizophreniaReview
      38. Beta-blocker supplementation of standard drug treatment for schizophreniaReview
      39. Bromperidol decanoate (depot) for schizophreniaReview
      40. Calcium channel blockers for neuroleptic-induced tardive dyskinesiaReview
      41. Cannabis and schizophreniaReview
      42. Carbamazepine for schizophreniaReview
      43. Case management for people with severe mental disordersReviewWithdrawn
      44. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisiaReview
      45. Cessation of medication for people with schizophrenia already stable on chlorpromazineReview
      46. Chinese herbal medicine for schizophreniaReview
      47. Chlorpromazine dose for people with schizophreniaReview
      48. Chlorpromazine for psychosis induced aggression or agitationReview
      49. Chlorpromazine versus atypical antipsychotic drugs for schizophreniaReviewNew
      50. Chlorpromazine versus placebo for schizophreniaReview
      51. Chlorpromazine versus reserpine for schizophreniaReview
      52. Cholinergic medication for neuroleptic-induced tardive dyskinesiaReview
      53. Clotiapine for acute psychotic illnessesReview
      54. Clozapine combined with different antipsychotic drugs for treatment resistant schizophreniaReview
      55. Clozapine versus other atypical antipsychotics for schizophreniaReview
      56. Clozapine versus typical neuroleptic medication for schizophreniaReview
      57. Cognitive behaviour therapy versus other psychosocial treatments for schizophreniaReview
      58. Cognitive behavioural therapy (brief versus standard duration) for schizophreniaReview
      59. Cognitive behavioural therapy versus other psychosocial treatments for schizophreniaReview
      60. Cognitive rehabilitation for people with schizophrenia and related conditionsReview
      61. Collaborative care approaches for people with severe mental illnessReview
      62. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personalityReview
      63. Compliance therapy for schizophreniaReview
      64. Compulsory community and involuntary outpatient treatment for people with severe mental disordersReview
      65. Containment strategies for people with serious mental illnessReview
      66. Crisis intervention for people with severe mental illnessesReview
      67. Dance therapy for schizophreniaReview
      68. Day centres for severe mental illnessReview
      69. Day hospital versus admission for acute psychiatric disordersReview
      70. Day hospital versus outpatient care for people with schizophreniaReview
      71. Depot fluspirilene for schizophreniaReview
      72. Depot haloperidol decanoate for schizophreniaReview
      73. Depot perphenazine decanoate and enanthate for schizophreniaReview
      74. Depot pipotiazine palmitate and undecylenate for schizophreniaReview
      75. Dietary advice for people with schizophreniaReview
      76. Distraction techniques for schizophreniaReview
      77. Drama therapy for schizophrenia or schizophrenia-like illnessesReview
      78. Droperidol for acute psychosisReview
      79. Early intervention for psychosisReview
      80. Educational games for mental health professionalsReview
      81. Electroconvulsive therapy for schizophreniaReview
      82. Estrogen for schizophreniaReview
      83. Exercise therapy for schizophreniaReview
      84. Family intervention (brief) for schizophreniaReview
      85. Family intervention for schizophreniaReview
      86. First rank symptoms for schizophreniaReviewDiagnostic
      87. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disordersReview
      88. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      89. Flupenthixol versus placebo for schizophreniaReview
      90. Fluphenazine decanoate (depot) and enanthate for schizophreniaReview
      91. Fluphenazine (oral) versus placebo for schizophreniaReview
      92. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      93. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesiaReview
      94. General physical health advice for people with serious mental illnessReview
      95. Glutamatergic drugs for schizophreniaReview
      96. Haloperidol dose for the acute phase of schizophreniaReview
      97. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)Review
      98. Haloperidol plus promethazine for psychosis-induced aggressionReview
      99. Haloperidol versus chlorpromazine for schizophreniaReview
      100. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disordersReview
      101. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      102. Haloperidol versus placebo for schizophreniaReview
      103. HIV prevention advice for people with serious mental illnessReview
      104. Horticultural therapy for schizophreniaReview
      105. Hypnosis for schizophreniaReview
      106. Implementation of treatment guidelines for specialist mental health careReview
      107. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illnessReview
      108. Information and communication technology based prompting for treatment compliance for people with serious mental illnessReview
      109. Information and communication technology in patient education and support for people with schizophreniaReview
      110. Intensive case management for severe mental illnessReview
      111. Intercessory prayer for the alleviation of ill healthReview
      112. Intermittent drug techniques for schizophreniaReview
      113. Interventions to encourage uptake of cancer screening for people with severe mental illnessReview
      114. Interventions to reduce weight gain in schizophreniaReview
      115. Lamotrigine for schizophreniaReview
      116. Length of hospitalisation for people with severe mental illnessReview
      117. Levomepromazine for schizophreniaReview
      118. Life skills programmes for chronic mental illnessesReview
      119. Lithium for schizophreniaReview
      120. Loxapine for schizophreniaReview
      121. Maintenance treatment with antipsychotic drugs for schizophreniaReview
      122. Management of sexual dysfunction due to antipsychotic drug therapyReview
      123. Miscellaneous treatments for neuroleptic-induced tardive dyskinesiaReview
      124. Molindone for schizophrenia and severe mental illnessReview
      125. Monetary incentives for schizophreniaReview
      126. Morita therapy for schizophreniaReview
      127. Mother and baby units for schizophreniaReview
      128. Music therapy for people with schizophrenia and schizophrenia-like disordersReview
      129. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesiaReview
      130. New generation antipsychotics for first episode schizophreniaReview
      131. Newer atypical antipsychotic medication versus clozapine for schizophreniaReview
      132. Nicotine for schizophreniaReview
      133. Nidotherapy for people with schizophreniaReview
      134. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesiaReview
      135. Olanzapine for schizophreniaReview
      136. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnessesReview
      137. Olanzapine versus other atypical antipsychotics for schizophreniaReview
      138. Open general medical wards versus specialist psychiatric units for acute psychosesReview
      139. Oral health advice for people with serious mental illnessReview
      140. Oral paliperidone for schizophreniaReview
      141. Outcome measures and needs assessment tools for schizophrenia and related disordersReview
      142. Paliperidone palmitate for schizophreniaReview
      143. Penfluridol for schizophreniaReview
      144. Perazine for schizophreniaReview
      145. Pericyazine for schizophreniaReview
      146. Perphenazine for schizophreniaReview
      147. Perphenazine versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      148. Pharmacological interventions for clozapine-induced hypersalivationReview
      149. Pharmacological treatments for psychosis-related polydipsiaReview
      150. Physical health care monitoring for people with serious mental illnessReview
      151. Pimozide for schizophrenia or related psychosesReview
      152. Polyunsaturated fatty acid supplementation for schizophreniaReview
      153. Preventive interventions for postnatal psychosisReview
      154. Problem solving skills for schizophreniaReview
      155. Prompts to encourage appointment attendance for people with serious mental illnessReview
      156. Psychoeducation (brief) for people with serious mental illnessReview
      157. Psychoeducation for schizophreniaReview
      158. Psychoeducation for siblings of people with severe mental illnessReview
      159. Psychosocial interventions for people with both severe mental illness and substance misuseReview
      160. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesiaReview
      161. Quetiapine for schizophreniaReview
      162. Quetiapine versus other atypical antipsychotics for schizophreniaReview
      163. Quetiapine versus typical antipsychotic medications for schizophreniaReview
      164. Risperidone (depot) for schizophreniaReview
      165. Risperidone dose for schizophreniaReview
      166. Risperidone versus olanzapine for schizophreniaReview
      167. Risperidone versus other atypical antipsychotic medication for schizophreniaReview
      168. Risperidone versus other atypical antipsychotics for schizophreniaReview
      169. Risperidone versus placebo for schizophreniaReview
      170. Risperidone versus typical antipsychotic medication for schizophreniaReview
      171. Seclusion and restraint for people with serious mental illnessesReview
      172. Sertindole for schizophreniaReview
      173. Sertindole versus other atypical antipsychotics for schizophreniaReview
      174. Smoking cessation advice for people with serious mental illnessReview
      175. Social skills programmes for schizophreniaReview
      176. Sulpiride augmentation for schizophreniaReview
      177. Sulpiride for schizophreniaReview
      178. Sulpiride versus placebo for schizophreniaReview
      179. Supported employment for adults with severe mental illnessReview
      180. Supported housing for people with severe mental disordersReview
      181. Supportive therapy for schizophreniaReview
      182. Testosterone for schizophreniaReview
      183. Thioridazine for schizophreniaReview
      184. Token economy for schizophreniaReview
      185. Training to recognise the early signs of recurrence in schizophreniaReview
      186. Transcranial magnetic stimulation (TMS) for schizophreniaReview
      187. Treatments for delusional disorderReview
      188. Trifluoperazine for schizophreniaReview
      189. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      190. Trifluoperazine versus placebo for schizophreniaReview
      191. Twenty-four hour care for schizophreniaReview
      192. User-held personalised information for routine care of people with severe mental illnessReview
      193. Valproate for schizophreniaReview
      194. Virtual reality for treatment compliance for people with serious mental illnessReview
      195. Vitamin E for neuroleptic-induced tardive dyskinesiaReview
      196. Vocational rehabilitation for people with severe mental illnessReview
      197. Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosisReviewDiagnostic
      198. Yoga versus standard care for schizophreniaReview
      199. Ziprasidone for schizophrenia and severe mental illnessReview
      200. Ziprasidone versus other atypical antipsychotics for schizophreniaReview
      201. Zotepine for schizophreniaReview
      202. Zotepine versus other atypical antipsychotics for schizophreniaReview
      203. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnessesReview
      204. Zuclopenthixol decanoate for schizophrenia and other serious mental illnessesReview
      205. Zuclopenthixol dihydrochloride for schizophreniaReview
      206. Zuclopenthixol versus placebo for schizophreniaReview
    3. Protocols
      1. Acceptance and Commitment Therapy for schizophrenia and related disordersProtocol
      2. Acetophenazine versus chlorpromazine for schizophreniaProtocol
      3. Acetylsalicylic acid (aspirin) for schizophreniaProtocol
      4. Allopurinol and related drugs for schizophreniaProtocol
      5. Amphetamines versus placebo for schizophreniaProtocol
      6. Animal-assisted therapy for people with serious mental illnessProtocol
      7. Anticholinergics for neuroleptic-induced parkinsonism and tardive dyskinesiaProtocol
      8. Anticholinergics (various) for neuroleptic-induced parkinsonismProtocol
      9. Anticholinergics versus placebo for neuroleptic-induced parkinsonismProtocol
      10. Antipsychotic combinations for schizophreniaProtocol
      11. Antipsychotics for people with persistent negative symptoms of schizophreniaProtocol
      12. Aripiprazole dose for schizophreniaProtocol
      13. Aripiprazole for neuroleptic induced hyperprolactinaemiaProtocol
      14. Aripiprazole for people with schizophrenia whose illness has been partially responsive to clozapineProtocol
      15. Aripiprazole for psychosis-induced aggression or agitationProtocol
      16. Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychosesProtocol
      17. Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychosesProtocol
      18. Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychosesProtocol
      19. Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychosesProtocol
      20. Asenapine versus other atypical antipsychotics for schizophreniaProtocol
      21. Asenapine versus typical antipsychotics for schizophreniaProtocol
      22. Atomoxetine for schizophreniaProtocol
      23. Avatar therapy for schizophrenia or related disordersProtocol
      24. Behavioural interventions for reducing weight gain in schizophreniaProtocol
      25. Bifeprunox versus placebo for schizophreniaProtocol
      26. Cariprazine versus placebo for schizophreniaProtocolNew
      27. Celecoxib for schizophreniaProtocol
      28. Chlorpromazine versus clotiapine for schizophreniaProtocol
      29. Chlorpromazine versus metiapine for schizophreniaProtocol
      30. Chlorpromazine versus penfluridol for schizophreniaProtocol
      31. Chlorpromazine versus piperacetazine for schizophreniaProtocol
      32. Clozapine augmentation for treatment-resistant schizoaffective disorderProtocol
      33. Clozapine dose for schizophreniaProtocol
      34. Cognitive behaviour therapy (group) for schizophreniaProtocol
      35. Cognitive behaviour therapy versus specific pharmacological treatments for schizophreniaProtocol
      36. Cognitive behaviour therapy versus standard care for schizophreniaProtocol
      37. Communication skills training for mental health professionals working with people with severe mental illnessProtocol
      38. De-escalation techniques for psychosis-induced aggression or agitationProtocol
      39. Different communication strategies for disclosing a diagnosis of schizophrenia and related disordersProtocol
      40. Electroconvulsive therapy for treatment-resistant schizophreniaProtocol
      41. Enhanced crisis planning for serious mental illnessProtocol
      42. Fluphenazine (oral) versus atypical antipsychotics for schizophreniaProtocol
      43. Haloperidol discontinuation for schizophreniaProtocol
      44. Haloperidol for long-term aggression in psychosisProtocol
      45. Illness management and recovery programme for people with severe mental illnessProtocol
      46. Iloperidone versus placebo for schizophreniaProtocol
      47. Increasing antipsychotic dose for non response in schizophreniaProtocol
      48. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophreniaProtocol
      49. Information and communication technology-based cognitive remediation for supporting treatment compliance for people with serious mental illnessProtocol
      50. Interventions for obsessive compulsive symptoms in people with schizophreniaProtocol
      51. Interventions for psychosis in adolescentsProtocol
      52. Interventions to reduce experiences of stigma and discrimination of people with mental illness and their caregiversProtocol
      53. Loxapine inhaler for psychosis-induced aggression or agitationProtocol
      54. Lurasidone versus placebo for schizophreniaProtocol
      55. Memantine for schizophreniaProtocol
      56. Mirtazapine (adjunct) versus placebo for schizophreniaProtocol
      57. Modafinil for schizophreniaProtocol
      58. Mood stabilisers for schizoaffective disorderProtocol
      59. Olanzapine depot for schizophreniaProtocol
      60. Olanzapine discontinuation for schizophreniaProtocol
      61. Operational Criteria Checklist for Psychotic Illness and Affective Illness (OPCRIT+) for diagnosing schizophrenia in people with psychotic symptomsProtocolDiagnostic
      62. Peer support for schizophreniaProtocol
      63. Pharmacological interventions for acute and transient psychotic disorder (ATPD)Protocol
      64. Pharmacological interventions for clozapine-induced sinus tachycardiaProtocol
      65. Pharmacological interventions for reducing weight gain in schizophreniaProtocol
      66. Pharmacological treatment for antipsychotic-related constipationProtocol
      67. Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illnessProtocol
      68. Psychological interventions for psychosis in adolescentsProtocol
      69. Quetiapine for psychosis-induced aggression or agitationProtocol
      70. Quetiapine versus placebo for schizophreniaProtocol
      71. Rehabilitation programmes for schizophreniaProtocol
      72. Relapse prevention for schizophreniaProtocol
      73. Risperidone for psychosis induced aggression or agitationProtocol
      74. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuseProtocol
      75. Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) for diagnosing schizophrenia in children and adolescents with psychotic symptomsProtocolDiagnostic
      76. Screening programmes for helping mental health professionals to detect violent victimisation in people with severe mental illnessProtocol
      77. Selective noradrenaline reuptake inhibitors for schizophreniaProtocol
      78. Self-help and guided self-help interventions for schizophrenia and related disordersProtocol
      79. Specialist interventions for homeless people with severe mental illnessProtocol
      80. Sulpiride dose for schizophreniaProtocol
      81. Sulpiride versus other antipsychotics for schizophreniaProtocol
      82. Switching antipsychotic for non response in schizophreniaProtocol
      83. Tai chi for schizophreniaProtocol
      84. Transitional discharge techniques for people with serious mental illnessProtocol
      85. Treatments for primary delusional infestationProtocol
      86. Typical antipsychotics for psychosis in adolescentsProtocol
      87. Unilateral electroconvulsive therapy versus bilateral electroconvulsive therapy for schizophreniaProtocol
      88. Yoga as part of a package of care versus standard care for schizophreniaProtocolNew
      89. Yoga versus non-standard care for schizophreniaProtocol
      90. Zotepine versus placebo for schizophreniaProtocol
  45. Cochrane Skin Group
  46. Cochrane STI Group
  47. Cochrane Stroke Group
  48. Cochrane Tobacco Addiction Group
  49. Cochrane Upper GI and Pancreatic Diseases Group
  50. Cochrane Urology Group
  51. Cochrane Vascular Group
  52. Cochrane Work Group
  53. Cochrane Wounds Group

SEARCH